MHRA Clarifies Licensing for Microbiome-Based Medicines
The MHRA has set out its position on microbiome-based medicinal products, confirming that a clear UK licensing route already exists for these therapies.
The MHRA has confirmed how microbiome-based medicinal products will be regulated in the UK, giving developers a clear route to market for the first time.
Published on 18 August 2026, the regulator's new position paper places these therapies firmly within existing UK medicines law, while flagging the scientific hurdles ahead.
No such product currently holds a UK licence, but that could soon change.
What the MHRA's Microbiome-Based Medicinal Products Position Says
Microbiome-based medicinal products, or MBMPs, work by modulating, restoring, or replacing the human microbiome.
The MHRA’s position paper states they fall within scope of the Human Medicines Regulations 2012, the same framework that governs all licensed UK medicines.
No MBMP holds a UK marketing authorisation yet. Two donor-derived microbiota products have already been licensed in the United States for recurrent Clostridioides difficile infection, giving UK developers a working precedent to build on.
Addressing Unmet Need and Antimicrobial Resistance
MBMPs are medicines that modulate, restore, or replace the human microbiome using live microorganisms or microbial consortia.
They fall within the Human Medicines Regulations 2012, meaning developers must meet the same standards of quality, safety, and efficacy as any licensed medicine.
The MHRA highlights MBMPs’ potential to tackle unmet clinical needs, including antimicrobial resistance (AMR), a global health threat where microbiome modulation could reduce infection recurrence and antibiotic dependence.
Developers must implement risk‑based safety strategies to assess AMR gene transfer and contamination risks, supported by validated analytical tools and transparent quality controls.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
How These Medicines Will Be Regulated
Depending on their composition, MBMPs may be regulated as biological medicinal products, or in some cases as advanced therapy medicinal products where the legal criteria are met.
The MHRA has outlined several areas developers must address before licensing is realistic:
- robust product characterisation, since composition can range from fixed formulations to tailored microbial consortia;
- control of manufacturing consistency and batch-to-batch variability;
- a risk-based safety strategy, including assessment of antimicrobial resistance risk;
- generation of robust clinical evidence of safety and benefit.
Why Faecal Microbiota Transplantation Sits Outside This Shift
Faecal microbiota transplantation, used mainly for recurrent C. difficile infection, is already available in the UK through clinical trials or as an unlicensed medicine under MHRA “specials” manufacturing arrangements.
These routes remain the prescribing clinician's responsibility and are unaffected by this publication.
What This Means for Developers Eyeing the UK Market
The position paper also addresses international divergence.
The EU’s Substances of Human Origin (SoHO) Regulation introduces a distinct framework for intestinal microbiota interventions from 2027. Under the Windsor Framework, that regulation will apply in Northern Ireland but not Great Britain, adding a layer sponsors must plan around.
The MHRA is encouraging early use of its Innovation Office and Scientific Advice service to agree development strategies before pivotal trials begin, a step that could meaningfully de-risk investment decisions.
A Regulatory Pathway to Licence Microbiome-based Medicinal Products
For sponsors developing microbiome-based medicinal products, the MHRA position paper turns an ambiguous regulatory idea into a workable pathway with a clear licensing route. Early engagement with the MHRA looks like the fastest way through it.
At Pharmatica, we analyse how regulatory shifts like this shape development strategy across regulatory and commercialisation. Explore more of our Insights to stay ahead of the policy decisions shaping pharma’s next moves.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What are microbiome-based medicinal products?
Microbiome-based medicinal products, or MBMPs, are medicines that treat disease by modulating, restoring, or replacing the human microbiome, typically using live microorganisms or microbial consortia.
Has the UK licensed any microbiome-based medicinal products?
Not yet. As of the MHRA's August 2026 position paper, no MBMP holds a UK marketing authorisation, although donor-derived microbiota products have been licensed elsewhere for recurrent C. difficile infection.
How will the MHRA regulate microbiome-based medicinal products?
The MHRA considers MBMPs to fall within the existing Human Medicines Regulations 2012, regulating them as biological medicinal products or, where applicable, as advanced therapy medicinal products.
Does the new MHRA position affect faecal microbiota transplantation?
No. Faecal microbiota transplantation remains available through clinical trials or unlicensed “specials” arrangements under clinician responsibility, unaffected by the new position paper.
How does the EU's SoHO Regulation affect UK microbiome developers?
From 2027, the EU's Substances of Human Origin Regulation will create a distinct framework for intestinal microbiota interventions, applying in Northern Ireland under the Windsor Framework but not in Great Britain.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)